Public Sector Pension Investment Board Boosts Holdings in Medtronic PLC $MDT

Public Sector Pension Investment Board grew its position in Medtronic PLC (NYSE:MDT) by 13.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 112,261 shares of the medical technology company’s stock after purchasing an additional 13,705 shares during the quarter. Public Sector Pension Investment Board’s holdings in Medtronic were worth $10,692,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Delos Wealth Advisors LLC purchased a new stake in Medtronic in the second quarter valued at about $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic during the third quarter valued at about $27,000. Valley Wealth Managers Inc. purchased a new position in shares of Medtronic in the 3rd quarter valued at approximately $29,000. Steigerwald Gordon & Koch Inc. acquired a new stake in Medtronic in the 3rd quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC purchased a new stake in Medtronic during the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on MDT shares. Needham & Company LLC upgraded shares of Medtronic from a “hold” rating to a “buy” rating and set a $121.00 price objective for the company in a research note on Monday, February 9th. Wells Fargo & Company assumed coverage on Medtronic in a research note on Friday, January 30th. They set an “overweight” rating and a $114.00 price target on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a report on Wednesday, November 19th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Finally, Leerink Partners set a $120.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $111.21.

Medtronic Stock Down 1.3%

Shares of MDT stock opened at $99.57 on Monday. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The stock has a market cap of $127.65 billion, a P/E ratio of 26.84, a P/E/G ratio of 2.62 and a beta of 0.71. The stock has a 50 day moving average of $99.28 and a 200 day moving average of $96.46. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the company earned $1.26 EPS. The business’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA cleared Medtronic’s Stealth AXiS system — an integrated planning, navigation and robotics platform for spine surgery that expands the company’s procedural addressable market and supports hardware/software recurring revenue potential. This is a material product‑launch catalyst for spine and future cranial/ENT applications. PR Newswire
• Positive Sentiment: Independent coverage and price‑target lifts: Barclays initiated coverage with an Overweight and $116 PT, and Needham upgraded to Buy with a $121 PT — both signal analyst conviction that recent product momentum and margins support upside from current levels. Benzinga Needham Upgrade
• Positive Sentiment: Market commentary highlights improving returns/operational momentum that could support multiple expansion if sustained — a constructive narrative for longer‑term investors. Yahoo Finance
• Neutral Sentiment: Q3 FY2026 earnings preview: analysts outline what to watch in the upcoming report (revenue cadence, procedure volumes, and guidance) — an event that could be a short‑term catalyst but not new information. MSN Earnings Preview
• Neutral Sentiment: Dividend/income writeups underscore MDT’s ~2.8% yield and ways to generate cash flow; supportive for income investors but a limited driver of near‑term price moves. Benzinga Dividend
• Negative Sentiment: Geopolitical and China exposure risks: analysis highlights tariffs and China’s volume‑based procurement (VBP) program as potential headwinds to margins and growth in a key market — a meaningful downside risk that can compress near‑term revenue and investor sentiment. Seeking Alpha

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).